Yuichiro Ukon, Satoshi Hosoya, Kazuki Morita, Yuji Yokozeki, Tomoko Kataoka, Takayuki Kitahara, Hirokazu Mae, Yuya Kanie, Masayuki Furuya, Takahito Fujimori, Takashi Kaito, Kiyoshi Okada, Akira Myoui, Seiji Okada
In Japan, the Act on Safety of Regenerative Medicine regulates unapproved regenerative medicine. Other nations market regenerative medicine products, bypassing regulatory approval. To identify unapproved orthopedic regenerative medicine, we have used data based on the Act. Platelet-rich plasma was often used. The common target was the knee. Prices averaged $2,490.
April 26, 2024: Stem Cell Reports